Silence Therapeutics plc

Management Reports • Nov 3, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9643V

Silence Therapeutics PLC

03 November 2014

3 November 2014

Silence Therapeutics plc

Additional listing

Silence Therapeutics plc, AIM: SLN, ('the Company'), announces that it has issued 48,667 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.

Application has been made for the 48,667 Ordinary Shares issued to be admitted to trading on AIM ("Admission"). Admission is expected to take place on Friday, 7 November 2014. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

The total number of shares in issue, following admission, will be 52,098,109.

Enquiries:

Silence Therapeutics plc	+44 (0)20 3700 9711
Timothy Freeborn, Finance Director & Company Secretary
Rozi Morris, Communications Manager
Canaccord Genuity Limited	+44 (0)20 7523 8350
Lucy Tilley/Dr Julian Feneley/Henry Fitzgerald-O'Connor

About Silence Therapeutics plc    (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNA interference (RNAi) or 'gene silencing' platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.

Silence is one of only a handful of listed companies globally which has human validated RNA delivery technology.  Its platform is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. Silence's RNAi platform has been used in three Phase 2 clinical trials, two awaiting results. It also has a robust IP estate protecting its proprietary technology.

This information is provided by RNS

The company news service from the London Stock Exchange

END

LISUGGWPGUPCGUW